Lettmann Jason — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Lettmann Jason is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $99K. Lifetime open-market sales: $28K.

Profile

Lettmann Jason

Jason Lettmann is the Chief Executive Officer of ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company. He has been involved in the company's strategic direction and development of its cancer treatment pipeline, including the CD47 blocker, evorpacept.

RoleInsider
Notability30/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-03-23ALXOALX ONCOLOGY HOLDINGS INCS — Open-market sale12.3K$2.17$27K
2026-02-20ALXOALX ONCOLOGY HOLDINGS INCF — Tax withholding / forfeiture2.2K$2.27$5K
2025-09-16ALXOALX ONCOLOGY HOLDINGS INCP — Open-market purchase71.2K$1.08$77K
2025-09-16ALXOALX ONCOLOGY HOLDINGS INCP — Open-market purchase21.1K$1.07$22K
2025-08-15ALXOALX ONCOLOGY HOLDINGS INCS — Open-market sale2.4K$0.64$2K

Frequently Asked Questions

Who is Lettmann Jason?

Jason Lettmann is the Chief Executive Officer of ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company. He has been involved in the company's strategic direction and development of its cancer treatment pipeline, including the CD47 blocker, evorpacept.…

Has Lettmann Jason been buying or selling stock?

Recorded transactions: 2 open-market purchases ($99K) and 2 open-market sales ($28K) across all tracked filings.

Where can I see all of Lettmann Jason's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Lettmann Jason profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.